Lanadelumab

Drug Profile

Lanadelumab

Alternative Names: Anti-plasma kallikrein mAb; Anti-plasma kallikrein monoclonal antibody; DX-2930; SHP 643

Latest Information Update: 01 Jun 2017

Price : $50

At a glance

  • Originator Dyax
  • Developer Shire
  • Class Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Plasma-kallikrein-inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hereditary angioedema
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Hereditary angioedema
  • Preclinical Diabetic macular oedema

Most Recent Events

  • 18 May 2017 Positive topline efficacy and adverse events data from the phase III HELP trial in Hereditary angioedema released by Shire
  • 13 Apr 2017 Dyax completes the phase III HELP study in Hereditary angioedema (Prevention, In children, In adolescents, In adults, In the elderly) in USA, Canada, Jordan, Germany, Puerto Rico, Canada, Italy and United Kingdom (SC) (NCT02586805)
  • 01 Mar 2017 Shire completes enrolment in its phase III trial for Hereditary angioedema (In adolescents, Prevention, In adults) in Canada, Germany, Italy, Jordan, the UK and the US (NCT02741596)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top